Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?

British Journal of Urology

Volumn 80, Issue 1, 1997, Pages 11-17

  Hofmockel, G ^a  

^a Department of Urology ^*  (Germany)

Author keywords

Immunohistochemistry; Multidrug resistance gene product; Prognosis; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0031400690     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00228.x     Document Type: Article

References (18)

1. Cordon-Cardo C, O'Brian JP. The multidrug resistance phenotype in human cancer. In DeVita VT, Hellman S, Rosenberg SA eds, Important Advances in Oncology 1991: 19-38
2. Kakehi Y, Kanamaru H, Yoshida O et al. Measurement of multidrug-resistance messenger RNA in urogenital cancers: elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988; 139: 862-5
3. Mickisch GH, Kössig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug
4. resistant primary human renal cell carcinomas. Cancer Res 1990; 50: 3670-4
5. Schneider J. Rubio M-P, Barbazan M-J, Rodriques-Eocudero FJ, Seizinger BR, Castresana JS. P-glycoprotein HER-2/neu and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994; 86: 850-5
6. Fojo A, Akiyama S, Gottesmann MM, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985; 45: 3002-7
7. Thibaut F, Tsuro T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sei USA 1987; 84: 7735-8
8. Cordon-Cardo C, O'Brian JP, Boccia J, Casals D, Bertino JR. Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-87
9. Duensing S, Dallmann I. Grosse J et al. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994: 51: 309-13
10. Kanamaru H. Kakehi Y. Yoshida 0, Nakanishi S, Pastan I. Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor expiants. J Natl Cancer Inst 1989; 81: 844-9
11. Weinstein RS, Jakate SM, Dominguez JM et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720-6
12. Hofmockel G, Tsatalpas P, Müller H et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 1995; 76: 296-306
13. van Kalken CK. van der Valk P. Hadisaputro MMN et al. Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney. Ann Oncol 1991; 2: 55-62
14. Naito S, Sakamoto N, Kotoh S. Goto K, Matsumoto T. Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993; 24: 156-60
15. Bak M Jr, Efferth T, Mickisch G, Mattern J. Volm M.
16. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 1990; 17: 72-5
17. 5 Volm M. Mattern J, Efferth T, Pommerenke EW. Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anlicancer Res 1992; 12: 1063-8
18. Morris MD. Bordow SB, Marshall GM, Haber PS. Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8